Cargando…
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
BACKGROUND: Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and worse prognosis. METHODS: This is...
Autores principales: | Basile, Debora, Parnofiello, Annamaria, Vitale, Maria Grazia, Cortiula, Francesco, Gerratana, Lorenzo, Fanotto, Valentina, Lisanti, Camilla, Pelizzari, Giacomo, Ongaro, Elena, Bartoletti, Michele, Garattini, Silvio Ken, Andreotti, Victoria Josephine, Bacco, Anna, Iacono, Donatella, Bonotto, Marta, Casagrande, Mariaelena, Ermacora, Paola, Puglisi, Fabio, Pella, Nicoletta, Fasola, Gianpiero, Aprile, Giuseppe, Cardellino, Giovanni G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463465/ https://www.ncbi.nlm.nih.gov/pubmed/30719874 http://dx.doi.org/10.1002/jcsm.12368 |
Ejemplares similares
-
The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer
por: Lisanti, Camilla, et al.
Publicado: (2022) -
Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Garattini, Silvio Ken, et al.
Publicado: (2021) -
Molecular classifications of gastric cancers: Novel insights and possible future applications
por: Garattini, Silvio Ken, et al.
Publicado: (2017) -
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker
por: Pelizzari, Giacomo, et al.
Publicado: (2019) -
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis
por: Gerratana, Lorenzo, et al.
Publicado: (2020)